(Press-News.org) DALLAS – May 28, 2013 – A new study on prostate cancer describes a novel class of drugs developed by UT Southwestern Medical Center researchers that interrupts critical signaling needed for prostate cancer cells to grow.
In men with advanced prostate cancer, growth of cancer cells depends on androgen receptor signaling, which is driven by androgens, such as testosterone. To thwart tumor growth, most patients with advanced prostate cancer receive drugs that block the production of androgen or block the receptor where the androgen binds. Unfortunately, such treatments invariably fail and patients die of prostate cancer with their androgen receptor signaling still active and still promoting tumor growth.
In the new study, available online at Nature Communications, a team of researchers led by Dr. Ganesh Raj, associate professor of urology at UT Southwestern, found that they could disrupt androgen receptor signaling using a novel class of drugs called peptidomimetics. This therapeutic agent consists of an engineered small protein-like chain designed to mimic peptides that are critical for androgen receptor function. The peptidomimetic agents block the activity of the androgen receptor even in the presence of androgen by attacking the protein in a different spot from where the androgen binds.
"We are hopeful that this novel class of drugs will shut down androgen receptor signaling and lead to added options and increased longevity for men with advanced prostate cancer," said Dr. Raj, the senior author of the study.
Dr. Raj compared the action that takes place to a lock and key mechanism. In prostate cancer, the androgen receptor (lock) is activated by the androgen (key) resulting in a signal that causes prostate cancer proliferation. In advanced prostate cancer, despite drugs targeting either the lock (androgen receptor) or the key (androgen production), there can be aberrant keys that open the lock or mutated locks that are always open, resulting in cancer cell proliferation. Instead of trying to block the lock or the key, peptidomimetics uncouple the lock and key mechanism from the proliferation signal. Thus, even with the androgen receptor activated, the prostate cancer cells do not receive the signal to proliferate and do not grow.
The researchers tested their drug in mouse and human tissue models. The novel drug proved non-toxic and prevented androgen receptor signaling in cancer cells. The response is highly promising and suggests that peptidomimetic targeting of prostate cancer may be a viable therapeutic approach for men with advanced disease.
Further testing is needed before a drug could move to Phase 1 clinical trials that involve human participants.
"Most drugs now available to treat advanced prostate cancer improve survival rates by three or four months," Dr. Raj said. "Our new agents may offer hope for men who fail with the current drugs."
These findings represent the development of a first-in-class agent targeting critical interactions between proteins. Other cellular and disease processes eventually could also be targeted with peptidomimetics, the scientists said.
Researchers identify novel class of drugs for prostate cancers
2013-05-28
ELSE PRESS RELEASES FROM THIS DATE:
Striking green-eyed butterfly discovered in the United States
2013-05-28
A new butterfly species from Texas, given the common name Vicroy's Ministreak, was discovered because of its striking olive green eye color, and was given a formal scientific name (Ministrymon janevicroy). This beautiful new butterfly may be the last truly distinctive butterfly species to be discovered in the United States.
Although individuals of Vicroy's Ministreak were deposited in the Smithsonian entomology collections a century ago, this species was unrecognized because it was confused with the common, similar-looking Gray Ministreak. Interestingly what distinguishes ...
Fast-sinking jellyfish could boost the oceans' uptake of carbon dioxide
2013-05-28
The oceans absorb about 25 percent of the carbon dioxide (CO2) emitted by human activities. Since the industrial revolution, they have taken up about half of the man-made CO2. Billions of planktonic organisms, too tiny to be seen with the naked eye, make this valuable service possible: When carbon dioxide from the atmosphere dissolves in seawater, various species convert it to organic carbon and other organic components during photosynthesis. Jellyfish and pelagic tunicates live on smaller plankton and thus consume organic carbon. When they sink to the seafloor at the end ...
Men, women lie about sex to match gender expectations
2013-05-28
COLUMBUS, Ohio – People will lie about their sexual behavior to match cultural expectations about how men or women should act – even though they wouldn't distort other gender-related behaviors, new research suggests.
The study found that men were willing to admit that they sometimes engaged in behaviors seen by college students as more appropriate for women, such as writing poetry. The same was true for women, who didn't hide the fact that they told obscene jokes, or sometimes participated in other "male-type" deeds.
But when it came to sex, men wanted to be seen as ...
Digital chest tomosynthesis possible lung cancer screening tool
2013-05-28
DENVER – Most lung cancers are detected when patients become symptomatic and have late-stage disease. However, recently, computed tomography (CT) screening for lung cancer has been reported to reduce lung cancer mortality. Since the National Lung Screening Trial's results showed a 20 percent reduction in lung cancer-specific deaths in those patients who had screening performed with chest CT, the use of CT screening for lung cancer has been gaining favor. However, CT is associated with the disadvantages of high radiation dosage and cost.
Digital chest tomosynthesis (DT), ...
Research highlights the increasing problem of prescription drug abuse among youth
2013-05-28
Young people are increasingly turning to prescription drugs to get high. Research out of the University of Cincinnati sheds new light on what could increase or lower that risk.
The research by Keith King, a University of Cincinnati professor of health promotion; Rebecca Vidourek, a UC assistant professor of health promotion; and Ashley Merianos, a graduate assistant in health promotion, is published in the current issue of the Journal of Primary Prevention.
The study focused on more than 54,000 7th- through 12th - grade students in schools across Greater Cincinnati, ...
Researchers provide rationale for use of targeted immunotherapy in sarcomatoid lung carcinomas
2013-05-28
DENVER – Sarcomatoid carcinomas of the lung include rare subtypes of poorly differentiated non–small-cell lung carcinomas of high grade and aggressive behavior. The biology of these neoplasms is poorly understood and these tumors are aggressive and resistant to chemotherapy and radiotherapy. The identification of actionable molecular targets for such infrequent and aggressive diseases is critical for design of new clinical trials.
Programmed death-1 (PD-1) is a co-inhibitory inducible receptor present on T-cells and macrophages. Tumor cells with increased programmed ...
Beer-pouring robot programmed to anticipate human actions
2013-05-28
ITHACA, N.Y. – A robot in Cornell's Personal Robotics Lab has learned to foresee human action in order to step in and offer a helping hand, or more accurately, roll in and offer a helping claw.
Video: https://www.youtube.com/watch?v=xaa_wEkCvG0
Understanding when and where to pour a beer or knowing when to offer assistance opening a refrigerator door can be difficult for a robot because of the many variables it encounters while assessing the situation. A team from Cornell has created a solution.
Gazing intently with a Microsoft Kinect 3-D camera and using a database ...
New ruthenium complexes target cancer cells without typical side effects
2013-05-28
A team of UT Arlington researchers has identified two ruthenium-based complexes they believe could pave the way for treatments that control cancer cell growth more effectively and are less toxic for patients than current chemotherapies.
Fred MacDonnell, professor of chemistry and biochemistry at The University of Texas at Arlington, has been researching a new generation of metal-based antitumor agents along with a team from the City of Hope Comprehensive Center Center in Duarte, Calif. Their aim is to find new therapies to complement widely used platinum-based therapies, ...
Shape-shifting nanoparticles flip from sphere to net in response to tumor signal
2013-05-28
Scientists at the University of California, San Diego, have designed tiny spherical particles to float easily through the bloodstream after injection, then assemble into a durable scaffold within diseased tissue. An enzyme produced by a specific type of tumor can trigger the transformation of the spheres into netlike structures that accumulate at the site of a cancer, the team reports in the journal Advanced Materials this week.
Targeting treatments specifically to cancerous or other diseased cells depends on some means of accumulating high levels of a drug or other therapeutic ...
For pundits, it's better to be confident than correct
2013-05-28
PULLMAN, Wash. - It would be nice to think the pundits we see yelling on TV and squawking on Twitter are right all the time. It turns out they're wrong more often than they are right.
Now two Washington State University economics students have demonstrated that it simply doesn't pay as much for a pundit to be accurate as it does to be confident. It's one thing to be a good pundit, but another to be popular.
"In a perfect world, you want to be accurate and confident," says Jadrian Wooten. "If you had to pick, being confident will get you more followers, get you more demand."
Wooten ...